Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Majalah Kedokteran Bandung Global Health Management Journal
Syifannisa, Ilma
Unknown Affiliation
Education Health Professions Medicine & Pharmacology Nursing Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Local Tumor Control Affects Survival of Patients with Osteosarcoma and Ewing Sarcoma Suryawan, Nur; Syifannisa, Ilma; Anantha, I Made Brahmystha Valqy
Majalah Kedokteran Bandung Vol 57, No 2 (2025)
Publisher : Faculty of Medicine, Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15395/mkb.v57.4082

Abstract

Osteosarcoma and Ewing sarcoma are the most common primary malignant bone tumors in children. This study aimed to analyze the characteristics of osteosarcoma and Ewing sarcoma patients at Dr. Hasan Sadikin General Hospital, Bandung, Indonesia, from 2020 to 2023 and compare the one-year survival rates between patients who underwent complete treatment (surgery for local tumor control and chemotherapy) and those who received chemotherapy alone. This study used a descriptive-analytical observational design with a retrospective approach by reviewing electronic medical records from the Indonesian Pediatric Cancer Registry (IPCAR). A total of 44 osteosarcoma patients and 14 Ewing sarcoma patients who met the inclusion criteria were included. The majority of patients were boys (osteosarcoma=61.36%; Ewing sarcoma=64.29%), with a mean age of 13.5 years for osteosarcoma and 9.1 years for Ewing sarcoma. Osteosarcoma was most commonly found in the femur and tibia (90.92%), whereas Ewing sarcoma was primarily located in the axial region (71.43%). Most patients underwent chemotherapy without local tumor control (osteosarcoma=61.36%; Ewing sarcoma=57.14%). The analysis revealed a significant difference in one-year survival between patients who received local tumor control combined with chemotherapy and those who underwent chemotherapy alone (osteosarcoma p=0.000; Ewing sarcoma p=0.010). In conclusion, local tumor control significantly improves one-year survival in both tumor types.
Sensitivity and Specificity of Pulse Oximetry for Congenital Heart Disease Screening in Newborn: A Meta-Analysis Syifannisa, Ilma; Valentine, Raden Ayu Libert Gatho Reza; Rangkuti, Dodo Islamuddin Khomara
GHMJ (Global Health Management Journal) Vol. 7 No. 3s (2024)
Publisher : Yayasan Aliansi Cendekiawan Indonesia Thailand (Indonesian Scholars' Alliance)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35898/ghmj-741020

Abstract

Background: Early detection for Congenital Heart Disease (CHD) using pulse oximetry is a routine procedure for newborn. Pulse Oximetry Screening (POS) has been shown to be effective in detecting CHD. Aims: To evaluate the accuracy of POS through sensitivity and specificity in detecting CHD.   Methods: In this meta-analysis, we conducted a search on Pubmed, Scopus, and ScienceDirect for studies that were published up to June 20, 2024. We selected studies that assessed the sensitivity and specificity of POS for the screening of CHD in newborn babies in a hospital or home setting, regardless of gestational age at birth and excluded newborns with a previous diagnosis of CHD. We used RevMan5 software (QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies-2) to assess the quality of the studies included and used Stata/SE 16.0 software to pool the sensitivity and specificity. Results: The results showed that 17 studies, including 413,516 newborns, had pooled sensitivity and specificity of 0.69 (95% CI: 0.57-0.81) and 0.93 (95% CI: 0.85-1.00). Conclusion: This study’s results suggest that POS has moderate sensitivity and high specificity in screening CHD in newborns. It can be concluded that there is a prospective usefulness of POS as a valuable tool in clinical practice for screening and management of CHD, especially in settings where access to higher diagnostic technologies may be limited.   Received: 25 September 2024  |  Reviewed: 20 October 2024  |  Revised: 13 November 2024  |  Accepted: 30 November 2024.
Co-Authors Anantha, I Made Brahmystha Valqy Rangkuti, Dodo Islamuddin Khomara Suryawan, Nur Valentine, Raden Ayu Libert Gatho Reza